First-line erdafitinib (± cetrelimab) shows antitumor activity with manageable safety in cisplatin-ineligible, FGFR-altered metastatic urothelial cancer
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Erdafitinib, with or without cetrelimab, has shown antitumor activity in patients with a specific type of metastatic urothelial cancer. The treatment has been found to have manageable safety in patients who are not eligible for cisplatin. This is in cases where the cancer has an FGFR alteration.